Technology
Experimental Drug AD109 Reduces Sleep Apnea Symptoms
A phase 3 trial found the experimental drug AD109 cut sleep apnea episodes by 44 percent versus 18 percent for placebo in 646 patients.
A phase 3 trial found the experimental drug AD109 cut sleep apnea episodes by 44 percent versus 18 percent for placebo in 646 patients.